suPAR (cut-off levels ⩽4, 4-6, and ⩾6 ng/mL) can predict the need for mechanical ventilation and mortality in patients with COVID-19 symptoms.

Listen to Jesper Eugen-Olsen, PhD, Senior Scientist at Copenhagen University Hospital Hvidovre and CSO at ViroGates, present the results of the study

More information about the study

suPAR is a biomarker associated with adverse outcomes. This study aimed to investigate the associations between plasma suPAR levels (testing the cut-offs ⩽4, 4-6, and ⩾6 ng/mL) with risk of 14-day mortality, and with the risk of mechanical ventilation in patients that tested positive for SARS-CoV-2.

This observational cohort study of 386 patients presenting symptoms of COVID-19 at the Department of Emergency Medicine, Amager and Hvidovre Hospital, Denmark from March 19th, 2020 to April 3rd, 2020, found suPAR levels predictive of mortality and the need for mechanical ventilation.

Consequently, validation of the findings was carried out in a similar-sized COVID-19 patient cohort from Mikkeli Central Hospital, Finland.

Conclusions:

Patients with symptoms of COVID-19 and suPAR ⩽4 or ⩾6 ng/mL had low or high risk, respectively, concerning the need for mechanical ventilation or mortality.

“It is essential to have the help of biomarkers, such as suPAR, which can support the discharge decision”

Juan González del Castillo, Dr PhD, Hospital Clínico San Carlos, Spain
suPAR News Vol. 1, April 2019

Want to know more about suPAR?

900+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPARnostic POC+

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates